Dezhan Healthcare Company Limited (SHE:000813)

Market Cap	9.16B +30.6%
Revenue (ttm)	396.16M -12.8%
Net Income	-357.73M
EPS	-0.17
Shares Out	2.10B
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	41,223,915
Average Volume	50,638,709
Open	3.940
Previous Close	4.370
Day's Range	3.940 - 4.360
52-Week Range	3.080 - 5.260
Beta	0.50
RSI	81.23
Earnings Date	Apr 25, 2026

About Dezhan Healthcare Company

Dezhan Healthcare Company Limited engages in the research and development, manufacture, and sale of cardiovascular and cerebrovascular drugs in the People’s Republic of China. The company offers atorvastatin calcium tablets, amlodipine atorvastatin calcium tablets, trimetazidine hydrochloride capsules, amiodarone hydrochloride tablets, as well as other drugs, including famciclovir tablets, azathioprine tablets, and hydroxyurea tablets and colchicine tablet. It also involved in the provision of biological peptides, industrial hemp, and medical s...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1980
• Employees: 1,067
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000813

Financial Performance

In 2025, Dezhan Healthcare Company's revenue was 396.81 million, a decrease of -14.94% compared to the previous year's 466.49 million. Losses were -345.42 million, 1592.2% more than in 2024.